# A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

> **NCT06285370** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Kyowa Kirin China Pharmaceutical Co., Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** Mogamulizumab

## Key facts

- **NCT ID:** NCT06285370
- **Lead sponsor:** Kyowa Kirin China Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-29
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-11-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06285370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06285370, "A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06285370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*